alpha-Thrombin (AT) and bradykinin (BK) are endogenous mediators that
are released during an inflammatory response, and could have a synergi
stic effect on endothelial permeability. Human umbilical vein endothel
ial cells (HUVEC) were grown on Transwell membranes and then tested fo
r alterations in permeability to fluorescein isothiocyanate-labeled hu
man serum albumin. Addition of 1 mu M AT produced a significant increa
se in the permeability coefficient at 30 minutes from control levels o
f 1.59 x 10(-6) cm/sec to 4.92 x 10(-6) cm/sec. BK (1 mu M) produced a
similar increase to 4.46 x 10(-6) cm/sec. For both compounds, permeab
ility remained elevated for 90 minutes. Pre-treatment of the HUVEC wit
h the bradykinin receptor antagonist, Na-adamantaneacetyl-bradykinin (
NA-BK) (1 mu M), prior to addition of AT, reduced the AT permeability
coefficient to 2.69 x 10(-6) cm/sec. Addition of NA-BK (1 mu M) for 5
minutes, then BK (1 mu M) for 5 minutes, inhibited the effect of BK an
d of AT (1 mu M) on permeability, decreasing the permeability coeffici
ent of the endothelial monolayer to control levels (1.62 x 10(-6) cm/s
ec). AT (1 mu M) increased HUVEC intracellular calcium mobilization, a
s monitored by FURA-2, to 245 nM from control (70 nM), however, pre-tr
eatment with either BK or the bradykinin receptor antagonist decreased
the AT induced intracellular calcium mobilization compared to AT alon
e. Pre-treatment of the HUVEC with bradykinin (1 mu M) for 2 minutes a
lso inhibited the effects of alpha-thrombin (1 mu M) on f-actin distri
bution examined by BODIPY-phallodin staining and increased the clottin
g times for an alpha-thrombin dependent fibrinogen to fibrin clotting
assay. However, incubation of bradykinin (1 mu M) with alpha-thrombin
(1 mu M) for either 10 minutes or 100 minutes produced no detectable h
ydrolysis products. These data strongly suggest that the inflammatory
mediators alpha-thrombin and bradykinin when released together, rather
than being synergistic, are antagonistic.